Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Supernus publicly promoted its proposed merger of equals with Indivior on August 3, 2026.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Supernus publicly promoted its proposed merger of equals with Indivior on August 3, 2026
- Employee communications indicate active merger preparation, but do not establish transaction completion
- Investors should monitor the forthcoming Form S-4 and joint proxy statement for exchange ratio, approvals, and closing conditions
- Fixed exchange ratio exposes shareholders to market-price risk before closing
- Additional debt financing for a Special Dividend could increase combined-company leverage after closing
Item EX-99.1 · Exhibit EX-99.1
- All-stock merger of equals with Indivior creates a broader CNS and behavioral-health platform
- Combined portfolio includes SUBLOCADE, Qelbree, Zurzuvae, Onapgo, and GOCOVRI
- Closing targeted for Q4 2026, subject to shareholder, regulatory, and other approvals
- Jack will become CEO, with Supernus leadership joining the expanded management team
- Fixed exchange ratio and potential financing for a Special Dividend create shareholder and leverage risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.